How have IMUCD shares performed in 2024?

ImmunoCellular Therapeutics' stock was trading at $0.2320 at the beginning of the year. Since then, IMUCD shares have decreased by 23.9% and is now trading at $0.1765. View the best growth stocks for 2024 here .

How do I buy shares of ImmunoCellular Therapeutics?

Shares of IMUCD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:IMUCD

ImmunoCellular Therapeutics (IMUCD) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free IMUCD Stock Alerts

$0.18

+0.03 (+17.59%)

(As of 04/18/2024 ET)

Compare

Today's Range: $0.18
▼
$0.20
50-Day Range: $0.13
▼
$0.30
52-Week Range: $0.16
▼
$0.51

Volume: 297 shs
Average Volume: 6,605 shs
Market Capitalization: $739,325.50

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart

Get ImmunoCellular Therapeutics alerts:

Ad Crypto Swap Profits

Did You Get Your Free Bitcoin Yet?

And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.

>> Register right here

About ImmunoCellular Therapeutics

ImmunoCellular Therapeutics, Ltd. is a clinical-stage company, which engages in the development of immune-based therapies for the treatment of cancers. The company's lead product candidate, ICT-107, is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. Its pipeline also includes ICT-121, a patient-specific, dendritic cell-based immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a patient-specific, dendritic cell-based immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T cells. The company was founded on January 30, 2006 and is headquartered in Calabasas, CA.

IMUCD Stock Price History

30 days | 90 days | 365 days | Advanced Chart

IMUCD Stock News Headlines

June 23, 2023 | finance.yahoo.com

RVVTF - Revive Therapeutics Ltd.

April 16, 2023 | thestreet.com

Blame for Northwest Bio Collapse Lies With CEO, Not With Mythical 'Wolfpack'

See More Headlines

Receive IMUCD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmunoCellular Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: OTCMKTS:IMUCD
CUSIP: N/A
CIK: N/A
Web: www.imuc.com
Phone: (818) 264-2300
Fax: N/A
Employees: 3
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 4,190,000
Free Float: N/A
Market Cap: $739,325.50
Optionable: Not Optionable
Beta: 1.63

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Gary S. Titus CPA (Age 60)
Independent Chairman & Corp. Sec.
Comp: $63k
Mr. Sanford J. Hillsberg (Age 71)
Co-Founder
Dr. John S. Yu (Age 56)
Founder & Director

Key Competitors

View All Competitors

IMUCD Stock Analysis - Frequently Asked Questions

How have IMUCD shares performed in 2024?: ImmunoCellular Therapeutics' stock was trading at $0.2320 at the beginning of the year. Since then, IMUCD shares have decreased by 23.9% and is now trading at $0.1765.
View the best growth stocks for 2024 here.
How do I buy shares of ImmunoCellular Therapeutics?: Shares of IMUCD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:IMUCD) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial